Nalotimagene Carmaleucel

Summary

Nalotimagene Carmaleucel (CHEMBL3990040) is a phase-3 clinical-stage gene; indicated across 6 conditions including leukemia and lymphoid neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Gene
• Indications: 6 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3990040
Name	Nalotimagene Carmaleucel
Type	Gene
Max phase	3

Also known as: HSV-TK, Nalotimagen carmaleucel, Nalotimagene carmaleucel, NALOTIMAGENE CARMALEUCEL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
leukemia	3	MONDO:0005059	EFO:0000565
lymphoid neoplasm	1	MONDO:0005157	EFO:0001642
astrocytoma (excluding glioblastoma)	1	MONDO:0019781	EFO:0000272
glioblastoma	1	MONDO:0018177	EFO:0000519
anaplastic astrocytoma	1	MONDO:0016684	EFO:0002499

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE2	3
PHASE1/PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00914628	PHASE3	TERMINATED	Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia
NCT01913106	PHASE1/PHASE2	RECRUITING	HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
NCT00423124	PHASE1/PHASE2	COMPLETED	Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies
NCT02831933	PHASE2	TERMINATED	Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma
NCT03004183	PHASE2	COMPLETED	SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
NCT03541928	PHASE2	UNKNOWN	Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).